XCellR8 Ltd, The Innovation Centre, Sci-Tech Daresbury, Daresbury, Cheshire, UK.
ALTEX. 2018;35(4):477-488. doi: 10.14573/altex.1710051. Epub 2018 Jun 13.
Skin sensitisers are substances that can elicit allergic responses following skin contact and the process by which this occurs is described as skin sensitisation. Skin sensitisation is defined as a series of key events, that form an adverse outcome pathway (AOP). Key event three in the AOP is dendritic cell activation that can be modelled by the human Cell Line Activation Test (h-CLAT) and is typified by changes in cell surface markers CD54 and CD86 in dendritic cells. The h-CLAT is accepted at a regulatory level (OECD Test-Guideline (TG)442E) and can be used to assess skin sensitisation potential as part of an integrated approach to testing and assessment (IATA). Stakeholders in the cosmetics and chemical industries have scientific and ethical concerns relating to use of animal derived material and have communicated a strong preference for fully human based in vitro methods. Therefore, we adapted the h-CLAT to animal-product-free conditions and validated the adapted method with the proficiency panel substances in Annex II of TG442E, using 3 independent batches of pooled human serum. The modified method showed equivalence to the validated reference method (VRM), as all proficiency substances were correctly classified. Comparable values for CV75 (concentration yielding 75% cell viability), EC150 and EC200 (concentration yielding RFI of ≥150 for CD86 and ≥200 for CD54) were obtained. Data generated using the adapted method may be used in European REACH submissions, provided the proficiency data is included. We are seeking formal inclusion of the adaptation into TG442E, enabling compliance with global regulations.
皮肤敏化剂是指那些在皮肤接触后能引发过敏反应的物质,而这一过程被描述为皮肤致敏。皮肤致敏被定义为一系列关键事件,形成一个不良结局途径(AOP)。AOP 的关键事件三是树突状细胞激活,这可以通过人类细胞系激活测试(h-CLAT)来模拟,其特征是树突状细胞表面标志物 CD54 和 CD86 的变化。h-CLAT 在监管层面上被接受(OECD 测试指南(TG)442E),可用于评估皮肤致敏潜力,作为测试和评估综合方法(IATA)的一部分。化妆品和化学工业的利益相关者对使用动物源性材料存在科学和伦理方面的担忧,并强烈倾向于完全基于人类的体外方法。因此,我们将 h-CLAT 适应于无动物产品的条件,并使用 TG442E 附件 II 中的熟练物质组验证了适应方法,使用了 3 批独立的混合人血清。改良方法与经过验证的参考方法(VRM)等效,因为所有熟练物质都被正确分类。对于 CV75(产生 75%细胞活力的浓度)、EC150 和 EC200(CD86 的 RFI 大于等于 150、CD54 的 RFI 大于等于 200 的浓度),得到了可比的值。使用适应方法生成的数据可用于欧洲 REACH 提交,前提是包括熟练数据。我们正在寻求将改编正式纳入 TG442E,以符合全球法规。